ID: MRFR/Pharma/1036-CR | December 2019 | Region: Global | 118 pages
Acute Pancreatitis Market Overview
Acute Pancreatitis Market is expected to register a CAGR of 5.91% to reach USD 7372.01 Million by 2025.
Acute pancreatitis is a systemic inflammatory response to autodigestion of the pancreas and peri-pancreatic organs that is excruciatingly painful and at times, fatal. The annual incidence of acute pancreatitis is 4.9 to 73 cases per 100,000 people worldwide, as per the NCBI. Acute pancreatitis is one of the most common gastrointestinal causes of hospitalization in the US. Over the past decade, despite the significant advances in critical care medicine, the mortality rate of acute pancreatitis has remained at approximately 10%. The diagnosis of pancreatic diseases can often be difficult, and treatments are delayed as the organ is inaccessible during the diagnosis.
The growth of the Market is attributed to rising prevalence of gallstones and high consumption of alcohol.
However, stringent regulations imposed by the FDA (Food and Drug Administration) is expected to hamper the growth of the market.
Acute Pancreatitis Market Key Players
The Prominent Players in the Market CalciMedica, SCM Lifescience, Samsung Bioepis, GNT Pharma Co., Baxter International Inc., B. Braun Melsungen AG, General Electric Company, Medtronic, Boston Scientific Corporation, and Fresenius Kabi USA.
The players operating in the acute pancreatitis market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
The Acute Pancreatitis Market has been segmented into Cause, Treatment & Diagnosis, and End User.
On the cause, the market has been segmented into gallstones, alcohol, and others. Gallstones accounts for 49.52% of the market share in this segment. Rising cases of gall stones worldwide and growing older population along with hereditary predispositions are major risk factors causing gall stones, which is driving the growth of the market.
Based on treatment & diagnosis, the market has been segregated into treatment and diagnosis. The treatment segment is further classified as intravenous fluid, nutritional support, analgesics, endoscopic retrograde cholangiopancreatography (ERCP), and others. The diagnosis segment is further classified as imaging tests and laboratory tests.
Based on end user, the market has been classified as hospitals & clinics and others.
Acute Pancreatitis Market Revenue, by cause, 2018 (% share)
Sources: MRFR Analysis
Acute Pancreatitis Market Regional Analysis
The Acute Pancreatitis is broadly segmented based on region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas accounted for a market share of 41.05% in 2018 due to the increasing prevalence of gall stones and alcohol consumption among the population and the availability of advanced healthcare facilities in the region. According to the National Institute of Diabetes and Digestive and Kidney Diseases, gallstones are very common, affecting 10% to 15% of the US population, which is nearly 25 million people. The acute pancreatitis in the Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada.
Europe was the second-largest global market in 2018. The European pancreatitis market has been segmented into Western Europe and Eastern Europe. The Western Europe Acute Pancreatitis market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the rest of Asia-Pacific. It holds the third-largest position in the acute pancreatitis market.
The acute pancreatitis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Global Acute Pancreatitis Market Share, by Region, 2018 (%)
Sources: MRFR Analysis
Gallstones are stones or lumps that develop in the gallbladder or bile duct. Approximately 20 million Americans are living with gallstones. The most common cause of acute pancreatitis is stones in the gallbladder. To enter the small intestine, gallbladder stones pass through the common bile duct. At the entry of the small intestine, the pancreas joins to the common bile duct. The gallstones that get stuck in the common bile duct impinge on the main pancreatic duct and obstructs the normal flow of pancreatic fluids, leading to pancreatic injury. Another way that a stone can cause pancreatitis is through the backflow of bile into the pancreatic duct that could result in a pancreatic lesion. The rising cases of gallstones are directly influencing the growth of the market.
Acute Pancreatitis Market, By Cause
Acute Pancreatitis Market, By Treatment & Diagnosis
Acute Pancreatitis Market, By End User
Acute Pancreatitis Market, by Region
Frequently Asked Questions (FAQ) :
Acute Pancreatitis Market is projected to grow at approximately 5.91% CAGR during the assessment period (2019-2025).
Acute Pancreatitis Market is estimated to reach a valuation of approx. USD 7372.01 MN by the end of 2025.
Rising prevalence of gallstones, high consumption of alcohol, and increasing investments and advancements in treatment procedures, are major tailwinds pushing the growth of the Global Acute Pancreatitis Market.
North America holds the largest share in the Global Acute Pancreatitis Market, followed by Europe and the Asia Pacific, respectively.
SCM Lifescience, General Electric Company, CalciMedica, B. Braun Melsungen AG, Samsung Bioepis, Medtronic, Boston Scientific Corporation, Baxter International Inc., Fresenius Kabi USA, and GNT Pharma Co., are some of the top players operating in the Global Acute Pancreatitis Market.